Rigel Pharmaceuticals Inc Asset Resilience Ratio
Rigel Pharmaceuticals Inc asset resilience ratio. Rigel Pharmaceuticals Inc (RIGL) has an Asset Resilience Ratio of 6.62% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Rigel Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rigel Pharmaceuticals Inc (2000–2025)
Asset resilience ratio of Rigel Pharmaceuticals Inc from 2000 to 2025. This chart shows how Rigel Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read RIGL total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Rigel Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Rigel Pharmaceuticals Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.51 Million | 6.62% |
| Total Liquid Assets | $34.51 Million | 6.62% |
Asset Resilience Insights
- Limited Liquidity: Rigel Pharmaceuticals Inc maintains only 6.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Rigel Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Rigel Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Rigel Pharmaceuticals Inc Asset Resilience Ratio by Year (2000–2025)
Rigel Pharmaceuticals Inc asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Rigel Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.27% | $114.38 Million | $513.59 Million | +9.72pp |
| 2024-12-31 | 12.55% | $20.57 Million | $163.98 Million | -8.05pp |
| 2023-12-31 | 20.60% | $24.15 Million | $117.22 Million | -4.53pp |
| 2022-12-31 | 25.13% | $33.75 Million | $134.28 Million | -38.26pp |
| 2021-12-31 | 63.39% | $106.08 Million | $167.33 Million | +38.97pp |
| 2020-12-31 | 24.42% | $26.95 Million | $110.38 Million | -26.78pp |
| 2019-12-31 | 51.20% | $75.56 Million | $147.57 Million | +13.67pp |
| 2018-12-31 | 37.54% | $52.22 Million | $139.11 Million | -27.50pp |
| 2017-12-31 | 65.03% | $77.46 Million | $119.11 Million | -8.09pp |
| 2016-12-31 | 73.12% | $57.13 Million | $78.13 Million | +10.26pp |
| 2015-12-31 | 62.86% | $82.82 Million | $131.75 Million | -20.15pp |
| 2014-12-31 | 83.02% | $127.96 Million | $154.13 Million | -1.53pp |
| 2013-12-31 | 84.55% | $191.12 Million | $226.06 Million | -0.85pp |
| 2012-12-31 | 85.39% | $264.76 Million | $310.04 Million | -3.68pp |
| 2011-12-31 | 89.07% | $229.01 Million | $257.11 Million | -1.14pp |
| 2010-12-31 | 90.21% | $168.42 Million | $186.69 Million | +5.94pp |
| 2009-12-31 | 84.27% | $118.60 Million | $140.74 Million | +22.77pp |
| 2008-12-31 | 61.50% | $88.47 Million | $143.86 Million | +6.41pp |
| 2007-12-31 | 55.09% | $63.79 Million | $115.79 Million | +4.98pp |
| 2006-12-31 | 50.11% | $56.74 Million | $113.24 Million | +8.52pp |
| 2005-12-31 | 41.59% | $61.42 Million | $147.67 Million | -35.71pp |
| 2004-12-31 | 77.30% | $60.93 Million | $78.82 Million | +10.88pp |
| 2003-12-31 | 66.42% | $36.88 Million | $55.52 Million | +64.71pp |
| 2002-12-31 | 1.70% | $756.00K | $44.34 Million | -45.50pp |
| 2001-12-31 | 47.21% | $21.93 Million | $46.45 Million | +41.04pp |
| 2000-12-31 | 6.17% | $3.96 Million | $64.26 Million | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more